Results 91 to 100 of about 46,300 (164)

Liraglutide for the treatment of type 2 diabetes : a single technology appraisal [PDF]

, 2011
This paper presents a summary of the Evidence Review Group (ERG) report into the clinical effectiveness and cost-effectiveness of liraglutide in the treatment of type 2 diabetes mellitus, based upon the manufacturer’s submission to the National ...
Cummins, E. (Ewen), Royle, Pamela, Shyangdan, D. (Deepson), Waugh, Norman   +3 more
core  

Incretin-Based Multi-Agonist Therapies for Type 2 Diabetes Mellitus and Obesity: Mechanisms, Clinical Efficacy, and Future Directions

Diabetology
Type 2 diabetes mellitus (T2DM) and obesity affect hundreds of millions of adults worldwide and represent leading drivers of cardiovascular disease, chronic kidney disease, and escalating healthcare expenditures.
Dhruba Podder, Olivia Stala, Atikul Miah, Abigail Agyapong, Madeline Elizabeth Moore, Rahim Hirani, Danielle Diegisser, Victor Garcia, Mill Etienne   +8 more
doaj   +1 more source

Comparative Effect of SGLT2 Inhibitors and GLP-1 Agonists on Glycemic Control in Type 2 Diabetes Mellitus

Journal of Pharmacy and Bioallied Sciences
Introduction: The goal of this study was to find out how SGLT2 inhibitors and GLP-1 receptor agonists help persons with Type 2 Diabetes Mellitus (T2DM) keep their blood sugar levels stable. Methodology: There were 120 people in the trial.
Ved Prakash, Sangeeta Gupta, Saumya Singh, Anurag Rawat, Amit Vasant Deshpande, Amrit Podder, Parth Jani   +6 more
doaj   +1 more source

Association of glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR) – a systematic review and meta-analysis

Frontiers in Medicine
ObjectivesPrevious studies have shown conflicting results on the relationship between glucagon-like peptide-1 (GLP-1) receptor agonists and diabetic retinopathy (DR). This systematic review and meta-analysis aimed to clarify the association between GLP-1
Hassan Alwafi, Sarah Saleh Al-Harbi, Ghada Ahmad Aladwani, Safaa M. Alsanosi, Tope Oyelade, Fahd Almalki, Husna Irfan Thalib, Abdallah Y. Naser, Manal Z. Alfahmi, Basil AlOtaibi, Samra Fuad, Mohammed Talha Mohammed Zubair, Abdulelah M. Aldhahir, Widya N. Insani, Abdullah A. Alqarni, Jaber S. Alqahtani, Deema S. Ashoor, Mohammad Saleh Dairi   +17 more
doaj   +1 more source

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. [PDF]

, 2017
Importance: Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.
Davies, Melanie, Hansen, Oluf K.H., Hartoft-Nielsen, Marie-Louise, Jabbour, Serge, Pieber, Thomas R., Rosenstock, Julio   +5 more
core   +1 more source

GLP-1 receptor agonists in Parkinson’s disease: an updated comprehensive systematic review with meta-analysis

Diabetology & Metabolic Syndrome
Previous studies have demonstrated an increased risk of developing Parkinson’s disease (PD) in patients with type 2 diabetes mellitus (T2DM), as well as more severe and rapid motor and non-motor deterioration in diabetic PD patients compared to their non-
Mohamed Mohsen Helal, Hala AbouShawareb, Omarfayez Hussein Abbas, Roaa Haddad, Youmna Zain, Ahmed S. A. Osman, Amr K. Hassan   +6 more
doaj   +1 more source

GLP-1 receptor agonists and conscious sedation. [PDF]

Interv Pain Med
Holder EK, Ni A, Levi D, International Pain and Spine Intervention Society's Patient Safety Committee.   +3 more
europepmc   +1 more source

The promise of GLP-1 receptor agonists for neurodegenerative diseases. [PDF]

J Clin Invest
Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S.   +4 more
europepmc   +1 more source

The emerging implications of GLP-1 receptor agonists in radiation therapy. [PDF]

Oncologist
Reinicke T, Dilworth JT.
europepmc   +1 more source

GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease. [PDF]

Int J Mol Sci
Gandhi A, Phyu EM, Koom-Dadzie K, Dickson KB, Halm J.   +4 more
europepmc   +1 more source